1. Home
  2. MGNX vs NTIC Comparison

MGNX vs NTIC Comparison

Compare MGNX & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.79

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Logo Northern Technologies International Corporation

NTIC

Northern Technologies International Corporation

HOLD

Current Price

$8.69

Market Cap

77.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
NTIC
Founded
2000
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
94.9M
77.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MGNX
NTIC
Price
$1.79
$8.69
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$3.20
N/A
AVG Volume (30 Days)
1.8M
37.3K
Earning Date
11-12-2025
01-08-2026
Dividend Yield
N/A
0.46%
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
$127,626,000.00
$84,234,474.00
Revenue This Year
N/A
$7.89
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4,702.95
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$6.75
52 Week High
$3.55
$13.64

Technical Indicators

Market Signals
Indicator
MGNX
NTIC
Relative Strength Index (RSI) 65.20 71.79
Support Level $1.54 $7.46
Resistance Level $1.89 $8.98
Average True Range (ATR) 0.10 0.36
MACD 0.03 0.14
Stochastic Oscillator 71.38 92.11

Price Performance

Historical Comparison
MGNX
NTIC

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About NTIC Northern Technologies International Corporation

Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.

Share on Social Networks: